Category Archives: Psoriasis

On Sunday, April 7, the National Psoriasis Foundation is hosting its annual Walk to Cure Psoriasis at the Aventura Mall (19501 Biscayne Blvd.). The event aims to raise funds for the Foundations research, education and advocacy programs.

Nationwide, as many as 7.5 million people are affected by the disease. Psoriasis, a noncontagious, chronic disease of the immune system, appears on the skin causing red, scaly patches. These patches, often painful and itchy, can appear on any part of the body. Additionally, up to 30 percent of people with psoriasis develop psoriatic arthritis. People with psoriasis are at risk of developing other serious conditions such as heart disease, diabetes and depression.

When: Sunday, April 7, 2013

Registration begins at 7 a.m., walk begins at 8 a.m.

Where: Aventura Mall19501 Biscayne Blvd.

Aventura, FL 33180

Cost: $25 registration fee. All participants will receive a t-shirt.

Choose between 1K and 5K routes on this walk to raise awareness and funds to combat psoriasis and psoriatic arthritis. All ages welcome.

To register or for more information, visit walk.psoriasis.org/sofla-walk, or call 877.825.WALK (9255).

Original post:
Walk to Cure Psoriasis

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/8rr8vz/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H1 2013" report to their offering.

This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis.

Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Psoriasis.

- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Psoriasis pipeline on the basis of route of administration and molecule type.

Read the original here:
Research and Markets: Psoriasis - Pipeline Review, H1 2013

Newswise A dermatology researcher at Case Western Reserve University School of Medicine has secured a five-year, $1.9 million federal grant to explore whether a specific molecule may play a pivotal role in the development and progression of psoriasis.

Nicole Ward, PhD, assistant professor of dermatology, is investigating whether interleukin-17C (IL-17C), a protein key to the regulation of the immune system, may also play a role in the onset and escalation of psoriasis, a chronic, debilitating skin disease that affects an estimated 7.5 million Americans.

The award, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, is the second Research Project Grant (R01) Ward has received in the last eight months. This grant will allow her to build upon earlier research suggesting a relationship between IL-17C and another protein (called TNF-alpha) in the emergence of psoriasis.

Psoriasis, an inflammatory autoimmune disease, is characterized by raised areas of red, scaly, itchy and sometimes painful patches of skin. Earlier this year, Ward and colleagues published an article in the Journal of Immunology that reported that psoriasis patients have elevated levels of IL-17C in their skin. Following treatment with TNF-alpha inhibitors, a standard therapy, IL-17C levels drop rapidly, even before the skin visibly improves. This development suggests that the presence, or interaction, of IL17-C and TNF-alpha are critical for the pathogenesis of the disease.

Ward and her colleagues also found that mice genetically engineered to overproduce IL-17C in the skin develop spontaneous lesions that resemble human psoriasis, suggesting a potential critical role for this molecule in disease initiation.. She now hopes to identify how IL-17C synergizes with other inflammatory molecules to cause diseasean understanding that may help identify a new target for drug development.

Although psoriasis is among the most common autoimmune diseases in the country, its cause remains unknown. While treatments to alleviate the condition exist, psoriasis has no cure. Patients are also more likely to be diagnosed with inflammatory bowel disease, cardiovascular disease, and depression. Even more troubling, psoriasis patients generally die seven to 10 years earlier than those without the disease.

Research funded by the NIAMS grant will be directed by Ward with collaborators and co-authors of the Journal of Immunology paper, Thomas McCormick, PhD, of Case Western Reserve, and Johann Gudjonsson, MD, PhD, and Andrew Johnston, PhD, of the University of Michigan.

In addition to the NIAMS grant, Wards research is supported by the National Psoriasis Foundation, the Murdough Family Center for Psoriasis and additional grants from the National Institutes of Health.

###

About Case Western Reserve University School of Medicine Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nations top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The Schools innovative and pioneering Western Reserve2 curriculum interweaves four themes--research and scholarship, clinical mastery, leadership, and civic professionalism--to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Nine Nobel Laureates have been affiliated with the School of Medicine.

Read more:
Case Western Reserve Awarded $1.9M Grant for Psoriasis Research

Psoriasis Free For Life is a newly updated treatment developed by Katy Wilson, who promises to give home remedies for psoriasis that can help sufferers treat psoriasis quickly and permanently. A full review on the site V-kool shows if the program is helpful for sufferers to use.

Seattle, Wa (PRWEB) April 01, 2013

A full review of Psoriasis Free For Life on the site V-kool points out that this is an effective and safe treatment method that can help sufferers get rid of psoriasis permanently. This new treatment method provides users with helpful tips, which can help them combat the skin problem quickly. This new guide offers three parts such as Diet Cleanse, Detoxifying and Secret Remedies that viewers should follow to achieve their goals in treating psoriasis. These parts give sufferers some detailed explanations about healthy foods they should eat in order to banish psoriasis effectively. In addition, the program supplies sufferers with lots of natural psoriasis treatments in PDF format, which are easy for them to understand and apply. This program also enables viewers to strengthen their immune system response, which can help them heal psoriasis permanently. Additionally, the new method gives up-to-date recipes with the goal of preparing some natural ointments, which will assist sufferers in the psoriasis treating process. The new method also helps viewers decrease the itchiness of pain quickly. In fact, this is an effective and helpful method that can help users banish their psoriasis problem forever, and they do not have to worry about getting it back again.

Kathryn Stone from the site Vkool.com says that: Psoriasis Free For Life is a new treatment that provides users with helpful home remedies for psoriasis, which can teach them how to treat psoriasis permanently. The new program provides users with lots of step-by-step guides that enable them to understand and follow it quickly. In other words, the new method will give a 24/7 supportive service whenever users need.

If people wish to view pros and cons from Psoriasis Free For Life, they could visit the website: http://vkool.com/treatment-for-psoriasis-psoriasis-free-for-life/

For those who desire to achieve instant access to view Psoriasis Free For Life review should visit the official site.

______________

About the website: V-kool is the site built by Tony Nguyen. The site supplies people with tips, ways, programs, methods and e-books about many topics including business, health, entertainment, and lifestyle. People could send their feedback to Tony Nguyen on any digital products via email.

Tony Nguyen V-kool 84915555999 Email Information

See more here:
Home Remedies For Psoriasis | How “ Psoriasis Free For Life” Helps People Treat Psoriasis Quickly – V-kool

Psoriasis Lotion Just Natural Skincare Review - For Dry Flaky Skin
Get it here: http://bit.ly/psoriasislotion Psoriasis isn #39;t acne, but psoriasis is often a skin condition that can go hand in hand with acne and dry skin. Thi...

By: acneerasingsecrets

See the rest here:
Psoriasis Lotion Just Natural Skincare Review - For Dry Flaky Skin - Video

UVB NARROWBAND UNITS - Treat psoriasis at home. SKIN MATTERS BRISTOL
UVB NARROWBAND - For treatment of Psoriasis and other skin conditions. Welcome to Skin Matters Bristol. We supply UVB Narrowband Units across the UK, deliver...

By: paul bristol

More:
UVB NARROWBAND UNITS - Treat psoriasis at home. SKIN MATTERS BRISTOL - Video

Public release date: 19-Mar-2013 [ | E-mail | Share ]

Contact: Andrew Lavin andrewlavin@alavin.com 516-944-4486 American Associates, Ben-Gurion University of the Negev

BEER-SHEVA, Israel, March 20, 2013 -- Ben-Gurion University of the Negev (BGU) researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis. The finding was reported in a new paper published in Chemistry and Biology.

Psoriasis is a chronic, non-contagious disease characterized by inflamed lesions covered with silvery-white scabs of dead skin. An auto-immune disease, psoriasis affects at least four million Americans. It is caused by the disturbance in the natural balance between pro-inflammatory signals and signals that inhibit inflammation.

One of the key signals involved in the progression of psoriasis is the immune system protein Interleukin 17 (IL-17). The research team developed a method to inhibit IL-17 pro-inflammatory signals and proved that their engineered receptor, IL-17R, is highly effective in reducing IL-17 induced inflammatory signals in mice models. Moreover, injection of the receptor into a mouse model with acute human psoriasis eliminated the symptoms, essentially curing the disease.

"Using directed evolution to improve the properties of the IL-17 receptor, we have created engineered mutants that might prove there is a viable treatment for patients with severe psoriasis that do not respond to current drugs," explains Dr. Amir Aharoni, one of the researchers in BGU's Department of Life Sciences and the National Institute for Biotechnology in the Negev.

"Since the directed evolution method can be applied to other receptors involved in autoimmune diseases and cancer, I believe that we are just starting to unravel the potential of this approach," Aharoni adds.

Directed evolution is an iterative Darwinian optimization process used in protein engineering whereby the fittest variants are selected from a collection of random mutations. Improved variants are identified and isolated by screening or selection for the property of interest. This approach is particularly advantageous in cases in which no prior knowledge of a protein's mechanism and structure is available.

The other researchers credited in "Directed Evolution of a Soluble Human IL-17A Receptor for the Inhibition of Psoriasis Plaque Formation in a Mouse Model" are BGU's Dr. Marianna Zaretsky and Teva researchers Dr. Liora Sklair-Tavron, Dr. Joel Kaye and Revital Etzyoni.

###

Follow this link:
Ben-Gurion U. researchers and Teva Pharmaceutical Industries Ltd. develop psoriasis drug

Ben-Gurion University of the Negev (BGU) researchers, in collaboration with Teva Pharmaceutical Industries Ltd., have developed a promising drug candidate to treat psoriasis. The finding was reported in a new paper published in Chemistry and Biology.

Psoriasis is a chronic, non-contagious disease characterized by inflamed lesions covered with silvery-white scabs of dead skin. An auto-immune disease, psoriasis affects at least four million Americans. It is caused by the disturbance in the natural balance between pro-inflammatory signals and signals that inhibit inflammation.

One of the key signals involved in the progression of psoriasis is the immune system protein Interleukin 17 (IL-17). The research team developed a method to inhibit IL-17 pro-inflammatory signals and proved that their engineered receptor, IL-17R, is highly effective in reducing IL-17 induced inflammatory signals in mice models. Moreover, injection of the receptor into a mouse model with acute human psoriasis eliminated the symptoms, essentially curing the disease.

"Using directed evolution to improve the properties of the IL-17 receptor, we have created engineered mutants that might prove there is a viable treatment for patients with severe psoriasis that do not respond to current drugs," explains Dr. Amir Aharoni, one of the researchers in BGU's Department of Life Sciences and the National Institute for Biotechnology in the Negev.

"Since the directed evolution method can be applied to other receptors involved in autoimmune diseases and cancer, I believe that we are just starting to unravel the potential of this approach," Aharoni adds.

Directed evolution is an iterative Darwinian optimization process used in protein engineering whereby the fittest variants are selected from a collection of random mutations. Improved variants are identified and isolated by screening or selection for the property of interest. This approach is particularly advantageous in cases in which no prior knowledge of a protein's mechanism and structure is available.

The other researchers credited in "Directed Evolution of a Soluble Human IL-17A Receptor for the Inhibition of Psoriasis Plaque Formation in a Mouse Model" are BGU's Dr. Marianna Zaretsky and Teva researchers Dr. Liora Sklair-Tavron, Dr. Joel Kaye and Revital Etzyoni.

Journal reference: Chemistry & Biology

Provided by American Associates, Ben-Gurion University of the Negev

View original post here:
Team develops psoriasis drug

MENLO PARK, California and BALLERUP, Denmark, March 18, 2013 /PRNewswire/ --

Virobay, Inc. and LEO Pharma A/S today announced that their collaboration on the development of an oral treatment for psoriasis has reached an important milestone as Virobay has now initiated a Phase 1 clinical trial of VBY-891 - a selective cathepsin S inhibitor.

(Logo: http://photos.prnewswire.com/prnh/20130221/595427 )

The first Phase 1 trial of VBY-891 is a double-blind, randomized, placebo-controlled study designed to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple escalating doses of VBY-891 in healthy adults.

"The initiation of this Phase 1 trial represents a significant development objective for Virobay's collaboration with LEO Pharma," stated Robert Booth, Ph.D., Chief Executive Officer of Virobay. "Virobay has plans to initiate clinical studies with additional cathepsin inhibitors during 2013 as we seek to develop new therapies for underserved diseases. Published prelinical data suggest that cathepsin S inhibition may provide a therapeutic benefit in patients with dermatological disorders such as psoriasis. In addition, our own preclinical data with selective cathepsin S inhibitors has demonstrated efficacy in models of both psoriasis and atopic dermatitis," stated Robert Booth. "We look forward to assessing the data from these Phase 1 trials, which will incorporate the evaluation of several biomarkers, to guide our Phase 2 clinical development plans for VBY-891."

"Reaching this important milestone in our collaboration with Virobay brings us one step closer to provide an oral treatment for psoriasis patients. We believe that VBY-891 has the potential to provide an oral treatment that may alleviate symptoms of psoriasis. LEO Pharma strives to constantly expand and improve treatment options for patients and this is an important example of our commitment to meeting patient needs. To the best of our knowledge, the VBY-891 compound has the potential to be the first in class on the market," said Kim Kjller, Senior Vice President, Global Development, LEO Pharma.

Background

About Cathepsin S and VBY-891

Cathepsin S is a member of the cysteine protease family of cathepsin inhibitors that catalyzes the final proteolytic step in the processing of invariant chain in specific antigen presenting cells. This step is essential in the maturation and loading of MHC Class II with antigenic peptides and subsequent activation of CD4+ T cells. Continuous presentation of antigenic self-peptides is thought to be involved in the maintenance of chronic disease in autoimmune disorders, including psoriasis. Inhibition of cathepsin S is likely to result in a reduction in antigen presentation without an impact on innate immunity.

VBY-891 is a next generation cathepsin S inhibitor that is a potent, competitive and reversible inhibitor of purified cathepsin S.It has picomolar inhibitory potency against the cathepsin S enzyme and nanomolar inhibitory potency in cellular assays. VBY-891 is also highly selective against human cathepsins L, B, F and K.Sustained cathepsin S inhibition after oral dosing has been demonstrated in vivo through the use of a biomarker. VBY-891 shows potent inhibitory activity in models of autoimmunity and neuropathic pain. Therefore, inhibition of cathepsin S may have therapeutic potential across a range of dermatological conditions.

Excerpt from:
Virobay and LEO Pharma Initiate a Phase 1 Trial of VBY-891, a Compound Intended for Oral Treatment of Psoriasis

Traitement du PSORIASIS
Watch Later Traitement Psoriasis La Gurison dUn Cas Extrmeby purealoevera 7037 views; 424. Watch Later Traitement psoriasis 10 solutions naturels contre le stressby Labosmascareignes 5818 views; 202. Watch Later Traitement naturel psoriasis acn eczma Sylvie Mliet raconte lhistoire des Labosby Labosmascareignes 13479 views; 131. Watch Later Traitement naturel efficace contre psoriasis et eczma Utilisation des soins Pso Naturaby Labosmascareignes 9103 views; 116. Watch Later ...

By: Best Line

See the article here:
Traitement du PSORIASIS - Video